The Effect of PPI on Endoscopic Treatment of WON: a Multicenter Randomized Controlled Trial.

Exclusion Criteria

• •1. Patients diagnosed with chronic pancreatitis who have not experienced an acute pancreatitis attack within the past three months.
• •2. Patients with severe coagulation disorders (International Normalized Ratio \[INR\] \> 1.5).
• •3. Patients with significant thrombocytopenia (platelet count \< 50 × 10\^9/L).
• •4. Pregnant women.
• •5. Patients undergoing endoscopic drainage solely through the duodenum.
• •6. Patients with a history of gastrectomy, gastric bypass surgery, or prior surgery for pancreatic-related diseases.
• •7. Patients currently taking medications that may affect gastric acid secretion or metabolism, such as strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., clarithromycin, itraconazole) or inducers (e.g., rifampin, carbamazepine).
• •8. Patients requiring long-term use of acid-suppressing medications such as PPIs and P-CABs due to other medical conditions.
• •9. Patients with a history of acid-suppressive medication use (e.g., PPI) and a washout period of less than 14 days.
• •10. Patients with documented contraindications to PPIs or a relevant history of hypersensitivity.